Bulletin
Investor Alert

Keros Therapeutics Inc.

NAS: KROS

GO
/marketstate/country/us

After Hours

 --Quotes are delayed by 20 min

Nov 30, 2020, 4:01 p.m.

/zigman2/quotes/217766474/composite

$

75.61

Change

0.00 0.00%

Volume

Volume 24,099

Quotes are delayed by 20 min

/zigman2/quotes/217766474/composite

Previous close

$ 76.00

$ 75.61

Change

-0.39 -0.51%

Day low

Day high

$69.68

$79.44

Open

52 week low

52 week high

$19.10

$81.00

Open

Annual Financials for Keros Therapeutics Inc.

Fiscal year is January-December. All values USD millions. 20182019 5-year trend
Sales/Revenue ---10M10M
Cost of Goods Sold (COGS) incl. D&A -----
COGS excluding D&A -----
Depreciation & Amortization Expense ---304,000438,000
Depreciation ---304,000438,000
Amortization of Intangibles -----
Gross Income -----
20182019 5-year trend
SG&A Expense ---11.39M20.13M
Research & Development ---10.11M17.38M
Other SG&A ---1.28M2.75M
Other Operating Expense -----
Unusual Expense ---43,0002.56M
EBIT after Unusual Expense ---(1.73M)(13.13M)
Non Operating Income/Expense ---650,000799,000
Non-Operating Interest Income ---6,000-
Equity in Affiliates (Pretax) -----
Interest Expense ----8,000
Gross Interest Expense ----8,000
Interest Capitalized -----
Pretax Income ---(1.08M)(12.34M)
Income Tax ---257,000-
Income Tax - Current Domestic ---257,000-
Income Tax - Current Foreign -----
Income Tax - Deferred Domestic -----
Income Tax - Deferred Foreign -----
Income Tax Credits -----
Equity in Affiliates -----
Other After Tax Income (Expense) -----
Consolidated Net Income ---(1.34M)(12.34M)
Minority Interest Expense -----
Net Income ---(1.34M)(12.34M)
Extraordinaries & Discontinued Operations -----
Extra Items & Gain/Loss Sale Of Assets -----
Cumulative Effect - Accounting Chg -----
Discontinued Operations -----
Net Income After Extraordinaries ---(1.34M)(12.34M)
Preferred Dividends ---1.01M1.8M
Net Income Available to Common ---(2.35M)(14.14M)
EPS (Basic) ---(0.12)(0.70)
Basic Shares Outstanding ---18.94M20.15M
EPS (Diluted) ---(0.12)(0.70)
Diluted Shares Outstanding ---18.94M20.15M
EBITDA ---(1.39M)(10.13M)
Link to MarketWatch's Slice.